TCR2 Therapeutics

TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
Cambridge, US
17 (est)-5%
TCR2 Therapeutics was founded in 2015 and is headquartered in Cambridge, US

TCR2 Therapeutics Locations

Cambridge, US

TCR2 Therapeutics Metrics

TCR2 Therapeutics Summary

Founding Date


Total Funding

$48.3 M

Latest funding size

$44.5 M

Time since last funding

about 1 month


We estimate that TCR2 Therapeutics's latest funding round in December 2016 was $44.5 M. In total, TCR2 Therapeutics has raised $48.3 M

TCR2 Therapeutics News

TCR2 Therapeutics Company Life

You may also be interested in